# InnoBio

> InnoBio is a VC fund in Nilai backing Medical, Biotechnology and Biopharma. See 4 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Nilai, Malaysia
- Total investments: 4
- Last investment: Jun 2018
- Lead investor: 0%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/inno-bio-ventures-sdn.-bhd.
- X (Twitter): https://www.twitter.com/innobiogroups
- Website: http://www.innobioventures.com
- Facebook: https://www.facebook.com/innobiologics

INNOBIO is a world leader in the extraction and refinement of high-purity natural plant bio-active ingredients and specialty products.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Medical | 2 | 50% |
| Biotechnology | 2 | 50% |
| Biopharma | 1 | 25% |
| Pharmaceutical | 1 | 25% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series B | 2 | 50% |
| Private Equity | 1 | 25% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| ENYO Pharma | ENYO Pharma is a biopharmaceutical company incorporated in Jan, 2014, by four scientists of the Infectiology Research Center in Lyon, France, and three seeding partners (2 privates and 1 public).The company is based in the Infectiology Center of Lyonbiopôle in Lyon, France and maintains tight collaborations with the seminal Inserm team and theBSL4 laboratory Inserm-Jean Mérieux.ENYO Pharma has licensed several Inserm patents issued from the discoveries of the founding scientists and developed a unique platform for the identification of intracellular therapeutic targets and molecules.The company is developing treatments against the most important viruses and is thriving to become a global leader in anti-virals. Research and Development is currently focused on human infecting viruses, with the first two programs being dedicated to the treatment of severe and seasonal flu and chronic hepatitis B. The company plans to conduct its molecules to Phase II clinical trials. | $42.4M | Series B | Jun 04, 2018 |  |
| Advicenne Pharma SA | Advicenne is a specialty pharmaceutical company dedicated to improving the lives of patients who suffer from rare renal diseases. | $17.6M | Private Equity | Mar 20, 2017 |  |
| Advicenne | Since its founding in 2007, Advicenne has been dedicated to developing and commercializing innovative treatments that address unmet medical needs in the area of nephrology. Our lead drug candidate, ADV7103, is in late-stage clinical trials for two indications: distal renal tubular acidosis (dRTA) and cystinuria. Listed on both the Euronext Parisand Euronext Brussels stock exchanges, the company is headquartered in Nîmes, France. | $18.2M | Private Equity | Mar 20, 2017 |  |
| MedDay | MedDay is an international pioneering fully integrated biopharmaceutical company.At MedDay, they believe that it is possible to treat neurodegenerative diseases by targeting key neurometabolic pathways.They strive to develop neuro repair disease modifying therapies and to provide solutions to patients, their caregivers and the healthcarecommunity, in order to improve patient care in areas of high unmet medical need.Promising clinical trial outcomes have encouraged us to date, and are continuing to drive us to pursue this direction.In daring to explore disrupted metabolic pathways in the central nervous system, their teams push the limits to improve future treatment options for patients suffering from neurodegenerative diseases. |  | Series B | Apr 08, 2016 |  |

4 of 4 investments shown.

## Co-investors
- [Bpifrance](https://shizune.co/investors/profile/bpifrance) — VC Fund, 4 deals together
- [Cemag Invest](https://shizune.co/investors/profile/cemag-invest) — VC Fund, 2 deals together
- [Andera Partners](https://shizune.co/investors/profile/edmond-de-rothschild-investment-partners) — VC Fund, 2 deals together
- [IRDI SORIDEC Gestion](https://shizune.co/investors/profile/irdi-soridec-gestion) — VC Fund, 2 deals together
- [IXO Private Equity](https://shizune.co/investors/profile/ixo-private-equity) — VC Fund, 2 deals together
- MI Care — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund
- [FJ Labs](https://shizune.co/investors/profile/fj-labs) — VC Fund

## FAQ

### What does InnoBio invest in?

InnoBio invests primarily in Medical, Biotechnology and Biopharma startups, most often at Series B and Private Equity stage. Most of the 4 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did InnoBio last invest?

The most recent investment recorded for InnoBio closed in Jun 2018. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co